Molecular epidemiology and antimicrobial susceptibility of enterococci recovered from Brazilian intensive care units by Almeida, Ricardo Titze de et al.
BJID 2004; 8 (June) 197
www.bjid.com.br
Molecular Epidemiology and Antimicrobial Susceptibility of Enterococci
Recovered from Brazilian Intensive Care Units
Ricardo Titze-de-Almeida1,4, Maurício Rollo Filho5, Molecular Microbiology and Biotechnology Laboratory
Celeste A. N. Silveira2, Isabela P. Rodrigues1,2, - MMB1, Infection Control Sector2 and Microbiology
João Eudes Filho3, Rejane S. do Nascimento5, Laboratory3 of the University Hospital of Brasília,
Renato F. Ferreira II1, Lídia M. P. Moraes4, Molecular Biology Laboratory, Institute of Biological
Hélène Boelens6, Alex Van Belkum6 and Sciences4 - University of Brasília, Public Health Bacteriology
Maria Sueli Soares Felipe4 Laboratory of Federal District5, Brasília, DF, Brazil;
Erasmus M.C., Department of Medical Microbiology
& Infectious Diseases6, Rotterdam, The Netherlands
We studied the antimicrobial resistance and the molecular epidemiology of 99 enterococcal
surveillance isolates from two hospitals of Brasília, Brazil. Conventional biochemical tests were
used to identify the enterococcal species and the disk diffusion method was used to determine
their resistance profiles. Enterococcus faecalis (76%) and E. faecium (9%) were the most
prevalent species. No enterococci showed the vanA or vanB vancomycin resistance phenotypes or
genotypes. Only the intrinsically resistant species E. gallinarum (n=2) and E. casseliflavus
(n=3) harbored the vancomycin-resistance genes vanC1 and vanC2/3, respectively. We found E.
faecalis isolates with high-level resistance to gentamicin (22%) and streptomycin (8%) and both
E. faecalis and E. faecium isolates with resistance to more than two antimicrobials (84% and
67%, respectively). Nine E. faecalis isolates (12%) were resistant to ampicillin; the minimal
inhibitory concentration (MIC) values were 16µg/mL (n=6) and 32µg/mL (n=3). Among these
ampicillin-resistant E. faecalis, seven were also resistant to gentamicin, ciprofloxacin, rifampin,
penicillin, chloramphenicol, tetracycline and erythromycin. Pulsed-field gel electrophoresis
classified those isolates in three different genotypes, suggesting dissemination of genetically
related ampicillin-resistant E. faecalis strains among different patients.
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Enterococci are opportunistic pathogens; they have
been recognized as an important cause of infective
endocarditis for almost a century. In addition, these
bacteria have also been recovered from urinary, wound,
and bloodstream infections [1]. The intrinsic (e.g.,
against cephalosporins and semisynthetic penicillinase-
resistant penicillins) and acquired (e.g., against
aminopenicillins and glycopeptides) resistance to
antibiotics is a subject of considerable concern [2,3].
First reported in Europe in 1987, vancomycin-resistant
enterococci (VREs) have received increasing attention
since the late 1980s, when a rapid rise in the numbers
of nosocomial infections was reported by the Center
for Disease Control and Prevention – CDC [4]. The
bacteria spread throughout the world, causing hospital
outbreaks of enterococcal infection and colonization
[5]. Several studies demonstrated that elevated
prevalences of VRE in health-care settings can
compromise the control of VRE dissemination,
reinforcing the importance of surveillance and early
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detection [3]. Since vancomycin-resistant E. faecium
and E. faecalis have already been isolated in other
regions of Brazil [6-13], we conducted a surveillance
study in Brasília city to determine the prevalence of
vancomycin resistance, the general antimicrobial
resistance profiles and the molecular epidemiology of
ampicillin-resistant E. faecalis isolates.
Materials and Methods
Bacterial isolates
A total of 99 enterococci were isolated from rectal
swabs from patients of intensive care units (ICU) of
two hospitals of Brasília (University Hospital of  Brasília
and Santa Luzia Hospital), Brazil, during a two-year
period (2000-2001).
Identification of bacterial isolates
Enterococci were identified on the basis of the
following criteria: Gram-positive staining, growth on bile-
aesculin agar and in 6.5% NaCl broth, absence of
catalase and presence of pyrrolidonyl arylamidase
(PYR Test Probac, Brazil). Species-level identification
was performed by standard biochemical tests: formation
of acid in mannitol, sorbitol, sucrose, arabinose,
raffinose, pyruvate and sorbose broth, pigmentation,
motility, growth on tellurite agar, and arginine hydrolysis
[14].
Susceptibility testing
The isolates were subjected to disk diffusion
antimicrobial susceptibility testing (Kirby-Bauer)
according to the National Committee for Clinical
Laboratory Standards (NCCLS) guidelines [15]. The
antibiotics (Oxoid, Basingstoke, UK) tested were
ampicillin, vancomycin, teicoplanin, ciprofloxacin,
tetracycline, chloramphenicol, penicillin, erythromycin,
rifampin; high-level resistance to gentamicin and
streptomycin was also assessed [16]. Isolates with
intermediate levels of susceptibility were classified as
resistant. The ampicillin-resistant isolates were
subjected to broth microdilution susceptibility testing
to determine the minimal inhibitory concentration
(ampicillin, Sigma, St. Louis, Mo., USA), based on
NCCLS guidelines [16,17]. The density of the inoculum
was first adjusted by suspending colonies in 0.9% saline
to the 0.5 McFarland turbidity standard. The bacterial
suspension was diluted 1:100 in cation-adjusted
Mueller-Hinton broth to obtain the desired final
inoculum concentration of colony-forming units (5 x
105 CFU/mL) in each well of the microdilution trays.
Colony-forming units on inoculum suspensions were
determined for each batch of tests. The plates were
incubated at 35°C for 16 to 20 hours.
Quality control
Staphylococcus aureus ATCC 25923 and E.
faecalis ATCC 29212 were used as quality control
reference strains according to NCCLS guidelines. We
performed quality control tests for the disks, disk
diffusion media and microdilution trays, using the
reference strains. In addition, the quality control strains
were tested along with the bacterial isolates in each
antimicrobial susceptibility test batch [15-17].
Pulsed-field gel electrophoresis (PFGE)
The bacterial genomic DNA was digested with Sma
I and the PFGE assay was performed according to
previous publications [18]. The samples were
electrophoresed on a BioRad CHEF mapper (block
1: run-time 10 h, switch time: 0.5 - 15 s and block 2:
run-time 8 h, switch time: 15-30 s, 6 V/cm, temperature
14ºC). Gels were stained with ethidium bromide and
photographed under UV irradiation. Isolates were
differentiated by visual inspection, and they were
classified according to generally accepted criteria [19].
Multiplex PCR
The multiplex PCR scheme that we developed
allows the simultaneous identification of enterococcal
species and vancomycin-resistance genes. The
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multiplex PCR assays were performed on material from
colonies touched with a sterile tip after overnight growth
on a blood agar plate. For each reaction, five to ten
colonies were suspended in 25 µL of a PCR mixture
containing the six pairs of primers described below: 10
mM Tris-HCl (pH 8.3); 50 mM KCl, 3.0 mM MgCl2;
0.25 mM of each deoxynucleotide triphosphate (dATP,
dCTP, dGTP, dTTP); and 2 U of Taq DNA
polymerase. The oligonucleotide primers used in the
PCR reaction, named according to the gene detected,
were: ddlE. faecalis, ddl E. faecium, vanC1, vanC2/3 (18.0
pmol of each primer), vanA (3.0 pmol of each primer)
[20], and vanB (1.5 pmol of each primer) [8]. The
tubes were overlaid with two drops of mineral oil. PCR
amplification was carried out with the following program:
initial denaturation step at 94ºC for 5 min, 30 cycles of
amplification (denaturation at 94ºC for 1 min, annealing
at 52ºC for 1 min, extension at 72ºC for 2 min), and a
final extension at 72ºC for 5min in a DNA thermocycler
PTC-100 (MJ Research, Inc, Waltham, MA, USA).
Fifteen-microliter samples of the PCR products were
electrophoresed through a 1% agarose gel stained with
ethidium bromide for 1 hour at 60 V. The gel was
photographed under UV light.
Results
Amongst the 99 isolates of Enterococcus spp., 75
were identified by biochemical tests as E. faecalis
(76%), 9 as E. faecium (9%), and 15% as other
species (five E. hirae, four E. raffinosus, two E.
gallinarum, three E. casseliflavus, and one E. avium)
(Table 1).
In vitro susceptibility patterns of the isolates were
determined (Table 1). None of the enterococcal isolates
were resistant to vancomycin or teicoplanin. Ampicillin-
resistance was detected in E. faecalis (12%) and absent
in E. faecium. In total, 28% of the E. faecalis and 11%
of the E. faecium were resistant to penicillin. The high-
level aminoglycoside resistance phenotype (HLAR) and
chloramphenicol resistance levels differed between E.
faecalis and E. faecium strains. Although none of the
E. faecium isolates expressed HLAR, 22% and 8% of
the E. faecalis were highly resistant to gentamicin and
streptomycin, respectively. A total of 37% of the E.
faecalis strains were resistant to chloramphenicol, as
opposed to none of the E. faecium strains.
The number of E. faecalis and E. faecium isolates
resistant to ciprofloxacin (79% and 56%, respectively),
rifampin (91% and 67%, respectively), tetracycline
(71% and 78%, respectively), and erythromycin (92%
and 89%, respectively) were high. Also, high
prevalences of resistance to two or more antimicrobials
were found in the E. faecalis and E. faecium isolates
(84% and 67%, respectively). In addition, seven
ampicillin-resistant E. faecalis isolates were also
resistant to gentamicin, ciprofloxacin, rifampin,
penicillin, chloramphenicol, tetracycline and
erythromycin.
Among the other enterococcal species, none
exhibited resistance to vancomycin, teicoplanin,
gentamicin, streptomycin or chloramphenicol.
Resistance to ampicillin (7%), ciprofloxacin (43%),
rifampin (29%), penicillin (21%), tetracycline (43%)
and erythromycin (29%) was found.
To evaluate the ability of the multiplex PCR
reaction to amplify the DNA targets, control strains
E. faecium, E. faecium (vanA), E. faecalis, E.
faecalis (vanA), E. faecalis (vanB), E. gallinarum
(vanC1), and E. casseliflavus (vanC2) were first
tested. The expected PCR products were observed
for all the control strains (Figure 1). In a second step,
multiplex PCR was performed on every isolate (Figure
1). The results obtained from PCR and from
phenotypic assays showed a high rate of agreement
for all the species, as follows: E. faecalis (95%), E.
faecium (95%), E. gallinarum (100%) and E.
casseliflavus (100%). As none of the enterococcal
isolates were resistant to the glycopeptide antibiotics,
vancomycin and teicoplanin, PCR products for vanA
and vanB genes were not found. As expected, no PCR
products were obtained for E. hirae, E. raffinosus,
and E. avium because of the absence of specific
primers for these species.
The nine ampicillin-resistant E. faecalis, detected
by the disk diffusion method, showed minimal inhibitory
concentrations (MIC) for ampicillin ranging from 16
Epidemiology and Resistance of Enterococci
200 BJID 2004; 8 (June)
www.bjid.com.br
Table 1. Antimicrobial resistance profile among Enterococcus spp.
Epidemiology and Resistance of Enterococci
Antimicrobial agent %
E. faecalis Vancomycin 0.0










E. faecium Vancomycin 0 0.0










Enterococcus spp.c Vancomycin 0 0.0










aIsolates with intermediate levels of susceptibility were classified as resistant.
bHigh-level resistance to gentamicin, streptomycin.
cIncludes five E. hirae, four E. raffinosus, three E. casseliflavus, two E. gallinarum, and one E.
avium.
Species
(no. of isolates; %)
Nº of resistant
enterococci isolatesa
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µg/mL (n=6) up to 32 µg/mL (n=3). Furthermore, seven
isolates with resistance to ampicillin were also resistant
to gentamicin, ciprofloxacin, rifampin, penicillin,
chloramphenicol, tetracycline and erythromycin. These
seven isolates, showing similar resistance phenotypes,
were typed by PFGE and classified into genotypes named
A (n=4), B (n=2), and C (n=1). Four representative
strains from these genotypes and also two examples of
ampicillin-susceptible E. faecalis with divergent
genotypes (D and E) are shown in Figure 2.
Discussion
Enterococci are part of the microbial communities
that colonize mammals, composing 1% of the human
intestinal microbiota. Among members of the genus
Enterococcus, E. faecalis and E. faecium are the
most common species isolated from human feces, and
they are the most common agents recovered from
enterococcal infectious diseases [3]. In our
investigation, E. faecalis (76%) and E. faecium (9%)
Figure 1. Agarose gel electrophoresis of multiplex PCR from enterococci isolates. The PCR products of the
control strains are shown in gel A, lanes: (1) Enterococcus faecalis ATCC 29212 (941 bp); (2) E. faecalis van-
B ATCC 51299 (941bp e 300bp); (3) E. faecalis van-A A256 (941bp e 732bp); (4) E. faecium (550bp); (5)
E. faecium van-A (550bp e 732bp); (6) E. casseliflavus (439bp); (7) E. gallinarum ATCC 12359 (822bp).
The PCR products of the isolates recovered from the individuals are shown in gel B, lanes: (1) E. faecium
(550bp); (2) E. faecalis (941 bp); (4) E. casseliflavus (439bp); (5) E. gallinarum (822 bp). Lane (3) molecular
size standard 100-bp DNA Ladder (Gibco/BRL Life Technology).
Figure 2. PFGE results of SmaI-digested chromosomal DNA from two ampicillin-susceptible Enterococcus
faecalis (lanes 6-7) and four ampicillin-resistant E. faecalis isolates resistant to gentamicin, ciprofloxacin, rifampin,
penicillin, chloramphenicol, tetracycline and erythromycin, representatives of the genotypes A, B, and C (lanes 2-
5). Lanes: 1 CHEF ladder standard (Biorad, Hercules, Calif., USA); 2 and 3 genotype A; 4 genotype B; 5
genotype C; 6 genotype D; 7, genotype E.
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were the most prevalent species colonizing the
gastrointestinal tract of patients from ICUs of two
hospitals of Brasília, Brazil. Similar results were
obtained for clinical isolates in other studies from Brazil
[10,21-23] and the United States [24]. These two
species were also the most prevalent enterococcal
isolates when considering only ICU isolations in studies
in Sweden and Lebanon [25, 26].
Enterococcal infections have received much attention
after the emergence of isolates resistant to glycopeptide
antibiotics [3,4]. VREs are uncommon nosocomial
pathogens in Europe [27], but they have been isolated
from livestock, small animals and healthy people [3,18].
In contrast, the community reservoir seems to be absent
in the USA, where VREs pose an alarming problem in
hospitals [5]. The first Brazilian VREs were isolated in
Paraná (1996) and São Paulo (1997), with vanD and
vanA phenotypes, respectively [6,7]. After that, VREs
were detected in hospitals from various cities, including
São Paulo, Marília, Rio de Janeiro, Uberlândia, and
Porto Alegre [8-13]. Due to the geographic dimensions
of Brazil, it was expected that each state would isolate
VRE at different times. We found no VREs in the
hospitals investigated in Brasília.
Several PCR protocols have been developed in
order to identify enterococcal species and to detect
glycopeptide resistance genotypes [20,28]. Woodford
et al. (1997) tested a multiplex PCR method on
bacterial colonies, with the same set of primers for
species identification used in our study [29]. They found
95% agreement between genotypic and phenotypic
methods, and they established the use of PCR to
identify enterococci submitted to the Laboratory of
Hospital Infection of the Central Public Health
Laboratory, London, United Kingdom [29]. In our
investigation, the primer concentration, annealing
temperature, and amplification cycles, were carefully
adjusted in order to develop a multiplex PCR assay
that allows the direct suspension of bacterial colonies
in the PCR mixture. The rate of agreement observed
between biochemical and PCR results (95% for E.
faecalis and E. faecium; 100% for E. gallinarum
and E. casseliflavus) showed that our multiplex PCR
protocol for bacterial colonies can be used for rapid
and reliable identification of enterococcal species (E.
faecalis, E. faecium, E. casseliflavus and E.
gallinarum).
Ampicillin, in association with gentamicin or
streptomycin, are the first choice drugs to treat severe
enterococcal infections [3]. Therefore, in the case of
HLAR, there is no synergism between the
aminoglycosides and b-lactams, which compromises
antibiotic therapy [1]. In our investigation, none of the
E. faecium isolates expressed HLAR, a result that
contrasts with previous publications [8,9]. However,
22% of the E. faecalis isolates were highly resistant to
gentamicin. Investigations conducted in other countries
found prevalences of gentamicin resistance in E.
faecalis ranging from 14% to 41% [26,30,31]. In
Brazil, previous publications have described resistance
to gentamicin in all E. faecalis strains found resistant
to vancomycin [8, 9]. In addition, we found that 8% of
the E. faecalis isolates had high-level resistance to
streptomycin. The streptomycin resistance prevalence
among the E. faecalis isolated during the first Brazilian
outbreak of vancomycin-resistant enterococci was
higher (22%) [8]. In contrast, Reis et al. (2001) found
absence of streptomycin resistance among the
vancomycin-resistant enterococci isolates that they
studied [9]. Stern et al. (1994) found a clear tendency
towards increasing enterococcal HLAR over the years
(e.g., 29%, 1985-1986; 55%, 1989-1990), which
could explain the differences in prevalence described
earlier [21]. Finally, previous investigations have shown
that endemic and high-level aminoglycoside resistant
isolates have gained vancomycin resistance genes,
which has been a subject of great concern [8,10].
Resistance to ciprofloxacin, rifampin, tetracycline, and
erythromycin was prevalent among E. faecalis and E.
faecium isolates. Zanella et al. (2003) have described
resistance to tetracycline (98%) and ciprofloxacin (96%)
in Brazilian vancomycin-resistant E. faecalis isolates [8].
Studies conducted in several countries (e.g. Poland, South
Africa, Lebanon, Kuwait, and Italy) have also found
prevalence of ciprofloxacin and tetracycline resistance
phenotypes among enterococci isolates [26,32-35]. In
addition, the presence of resistance genes within
transferable genetic structures, such as plasmids, enables
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the horizontal spreading of resistance among isolates [2].
In a recent study, it was observed that mobile genetic
elements account for more than a quarter of the complete
E. faecalis V583 genome and, consequently they play
important roles in the acquisition and dissemination of drug
resistance among enterococci [36].
Resistance to ampicillin, the drug of choice for
enterococcal infections, was observed in 12% of the
E. faecalis isolates in our investigation. The prevalence
rate was near that observed during the first Brazilian
vancomycin-resistant outbreak (9.4%), which occurred
in São Paulo [8]. D’Azevedo et al. (2001) have also
found a similar rate of resistance to ampicillin (10%)
among vancomycin-resistant E. faecalis recovered
from Porto Alegre city, in southern Brazil [37]. In
contrast, ampicillin-resistance was absent among
vancomycin-resistant E. faecalis isolates from another
study [9]. A remarkable variation in the E. faecalis
ampicillin resistance prevalence has been found in
various countries, as follows: Poland (0%), Lebanon
(0.9%), South Africa (1.4%), Brazil, Argentina, Chile,
and Ecuador (1-7%), Croatia (5.2%), and Italy (17%)
[26,32-34,38,39].
The ampicillin-resistant E. faecalis isolates in our
investigation had MIC values ranging from 16 µg/mL
to 32 µg/mL, being classified as resistant (MIC ≥ 16
µg/mL) [16]. However, some authors consider that
ampicillin would be useful to treat infections (e.g. lower
urinary tract infection) caused by enterococci with MIC
for ampicillin ≤ 64 µg/mL [1]. This antibiotic therapy
would avoid the use of glycopeptides and newer drugs
(e.g. linezolid), thus reducing the selective pressure for
resistant isolates [3].
Interestingly, no E. faecium isolates showed
resistance to ampicillin in our investigation. This
resistance phenotype occurred in 100% of the
vancomycin-resistant E. faecium of the first Brazilian
outbreak and among isolates recovered from different
hospitals of the cities of São Paulo and Curitiba [8,9].
Data gathered from a recent investigation, as part of
an international surveillance program, called GSMART
(Global Synercid Microbiologic Assessment of
Resistance Trends), described the ampicillin resistance
prevalence among Latin America countries, including
Brazil, Argentina, Chile, Ecuador and Venezuela [38].
We considered this a representative study of the
Brazilian enterococcal resistance profiles, because it
included isolates from four different cities (São Paulo,
Rio de Janeiro, Florianópolis and Porto Alegre). In
addition, 81% of the vancomycin-resistant E. faecium
isolates were from Brazil. In that investigation, Sader
et al. (2001) found resistance to ampicillin in 100% of
the vancomycin-resistant E. faecium, which
corroborated previous publications [8,9,38]. However,
most of the vancomycin-susceptible E. faecium were
susceptible to ampicillin (72% to 84%). We also found
a high prevalence of susceptibility to ampicillin (100%)
among vancomycin-susceptible E. faecium isolates,
corroborating the GSMART results.
In our study, seven ampicillin-resistant E. faecalis
isolates showing resistance to gentamicin, ciprofloxacin,
rifampin, penicillin, chloramphenicol, tetracycline and
erythromycin were isolated from different UTI patients
from the University Hospital of Brasília. The PFGE
analysis of the seven ampicillin resistant E faecalis
isolates with multiple resistance phenotypes revealed
three different genotypes, named A, B, and C.
Genotype C was represented by only one isolate.
However, four and two isolates from different patients
shared genotypes A and B, respectively. These endemic
clones (types A and B) spread among patients during
different periods of time. Previous investigations
performed in several countries, including Brazil, have
described intra and inter-hospital spread, as well as
persistence of genetically related VREs [9,40]. In
addition, vanA and vanB genes have been incorporated
into endemic ampicillin-resistant vancomycin-sensitive
E. faecium [41,42]. The long-term presence of
genetically related enterococcal lineages in nosocomial
wards, and the relationship between resistance and
virulence are factors that drive local epidemiology and
bacterial evolution [3,43]. A previous publication found
both ampicillin resistance and presence of the esp gene
as associated events among vancomycin-sensitive E.
faecium isolates [44].
In conclusion, none of the enterococcal isolates from
the Brasília ICUs were resistant to vancomycin or
teicoplanin, and most of them remain susceptible to
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ampicillin. In contrast, the prevalence of HLAR, the
resistance patterns found, and the clonal dissemination
of endemic ampicillin-resistant E. faecalis are subjects
of concern. We suggest actions promoting the rational
use of antibiotics in health-care settings, the execution
of surveillance studies in order to monitor changes in
enterococcal resistance patterns and the adoption of
measures to prevent the spreading of genetically-related
resistance isolates.
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